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Key Points 
 Few studies have been conducted to examine the relationship between anticholinergic 
burden (ACB) and stroke in a general population.  
 In this prospective cohort study including 21,722 participants, we demonstrated an 
increased in risk of incident stroke and stroke mortality with increasing anticholinergic 
burden. 
 Our results provide incentive to clinicians to cautiously use medications with 
anticholinergic properties to reduce the global burden of stroke.   
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Abstract 
Background: Stroke is primarily a disease of older age with a substantial impact on global 
mortality and morbidity. Whilst medications with anticholinergic effects are widely used, no 
studies have been conducted to examine the relationship between anticholinergic burden 
(ACB) and stroke in a general population. 
Method: The sample was drawn from the EPIC-Norfolk cohort. Baseline assessments were 
carried out during 1993-1997 and participants were followed up until March 2016. 
Participants were divided into 4 groups according to their total ACB score at baseline, these 
groups were those with a total ACB score of 0, 1, 2-3 and >3. After exclusion, Cox-
proportional hazards models were constructed to determine the associations between the 
ACB score groups and the risk of incident stroke and stroke mortality. Sensitivity analysis 
and propensity score matched analyses were performed.  
Results: In total 25,639 participants attended the first health check, 3,917 participants were 
excluded, leaving 21,722 participants to be included. Participants had a mean age (SD) of 
58.9 (9.2) years (54.4% women). Of these, 2,131 suffered incident stroke and 562 died 
from stroke. Mean follow up was approximately 18 years for both outcomes. In the fully 
adjusted model, those with an ACB of >3 had 59% relative risk of incident stroke (HR (95% 
CI) 1.59 (1.34 - 1.89)) and 86% relative risk of stroke mortality (1.86 (1.37 - 2.53)) 
compared to those in ACB 0 category. Sensitivity analyses and propensity score matched 
analyses showed similar results.   
Conclusions: Our results provide an incentive for the cautious use of medications with 
anticholinergic properties to help reduce the global burden of stroke.   
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Introduction 
Polypharmacy is a common factor in ageing populations. As such, the appropriate use of 
medications with anticholinergic (antimuscarinic) adverse effects is of particular interest due 
to their additive effects, age related changes to pharmacokinetic and pharmacodynamics 
properties and the wide range of therapeutic categories in which they occur. These 
medications are prescribed frequently, with studies in older adults reporting the prevalence 
of anticholinergic medications ranging from 8-37% depending on the study setting (1, 2, 3). 
 
Recently, there have been studies published examining a link between anticholinergic 
burden (ACB) and health outcomes in general populations. We have recently shown an 
association between ACB and risk of all-cause mortality and incident cardiovascular 
disease, describing a class effect as well as a dose response relationship (4). A large study, 
part of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS), 
showed an increase in the cumulative risk of cognitive impairment and mortality in 
approximately 13,000 participants aged 65 and over (5). Another study in approximately 
2,600 participants aged over 65, part of The Irish Longitudinal Study on Ageing (TILDA) 
showed an association with subsequent injurious falls in older men (6). In addition, other 
studies have been carried out examining for a link between ACB and health outcomes, but 
these have primarily focused on specific patient populations (7, 8, 9, 10).  
 
Importantly, previous studies in general populations have not examined for stroke outcomes 
and whilst some studies have been published on the link between ACB and stroke, these 
have been in specific patient populations, focusing primarily on inhaled anticholinergics in 
COPD patients producing mixed results (11, 12). An important gap in the literature exists 
regarding risk of stroke and ACB in a general population.  
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Stroke represents one of the most common and significant life changing events, affecting 
15 million people worldwide leading to substantial mortality and morbidity, with an estimated 
annual cost to the European economy of €64.1 billion (13). Stroke is primarily a disease of 
older age, and with the increase in ageing populations the global incidence of stroke is 
expected to rise across the world’s regions despite improved risk factor management. As 
stroke is a potentially preventable condition, the link between ACB and risk of stroke would 
have an important impact on clinical practice globally as it represents an easily identifiable 
and potentially modifiable risk factor. 
 
Therefore, in this study, we examined the prospective relationship between total ACB from 
medications at baseline and incident stroke and stroke mortality in a UK population based 
study, European Prospective Investigation into Cancer (EPIC)-Norfolk. 
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Methods 
Population 
The study population was drawn from men and women participants aged between 39 - 79 
years at the baseline (1993-1997) who took part in the EPIC-Norfolk prospective 
population-based study. The study protocol of EPIC-Norfolk has been described previously 
(14). In brief, participants were invited from general practice age-sex registers between 
1993-1997 and followed up to March 2016.  In total 25,639 participants (99∙6% White 
British) attended a baseline health examination during 1993-1997.  
 
Ethics 
Ethical approval was obtained from the Norwich Ethics Committee and all participants gave 
informed signed consent for the examination of medical records and use of data. 
 
Measurement methods 
 
Details of data collection and measurement methods are described in full as part of the 
online content. In summary, at baseline, participants completed a health and lifestyle 
questionnaire in which information such as educational status, social class, physical 
activity, smoking status, alcohol consumption, prevalent illness and medications were 
asked.  Other physiological and biological parameters such as height, weight, blood 
pressure and non-fasting venous blood samples were collected by trained research nurses 
at clinic visits.  
 
Drugs associated with anti-cholinergic burden (Appendix 1) were identified by searching 
the database for exact and similar entries for both generic and brand name drugs.  Each 
medication was assigned to the corresponding anti-cholinergic score and the total 
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anticholinergic burden (ACB) was calculated using the formula: {[number of class 1 anti-
cholinergic drugs] + [the number of class 2 anti-cholinergic drugs x 2] + [the number class 3 
anti-cholinergic drugs x 3]}.   
 
The development of the anti-cholinergic burden (ACB) scale used in this study has been 
previously reported. Classification of drugs with ACB was class 0 (none), class 1 (mild), 2 
and 3 (severe). Examples of drugs with include atenolol, ranitidine, codeine (class 1), 
amantadine, carbamazepine, pethidine (class 2) and amitriptyline, oxybutynin, olanzapine 
(class 3).  The score’s predictive validity in cognitive decline has been shown in three large 
scale studies and a score of 2 or more was associated with increased mortality in an older 
population (15). 
 
Participants were divided into 4 groups according to their ACB score at baseline. These 
groups were those with baseline ACB score of 0, 1, 2-3 and >3. 
 
Case ascertainment 
Stroke mortality of participants was identified from the Office of National Statistics and 
admission episodes were identified from the NHS hospital information system and 
ENCORE (East Norfolk COmmission Record). Stroke mortality and incident stroke were 
identified from the death certificates or hospital discharge code ICD 9, 430-438, or ICD 10, 
I60-I69 for stroke incidence. The follow up protocol of EPIC-Norfolk had been previously 
validated using incident stroke cases which showed high sensitivity and specificity (16). 
 
Follow up time for this study started at the date of study enrolment and ended in March 
2016 for both incident stroke events and stroke mortality outcomes. 
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Exclusion criteria 
As shown in Appendices 2 and 3, of 25,639 participants attended first health check, 3,917 
participants were excluded from analysis due to prevalent stroke and missing data, leaving 
21,722 participants included in the analysis. 
 
Statistical analysis  
Data were analysed using SPSS version 24.0 (SPSS Inc., Chicago, IL, USA) and Stata 
14.0 (StataCorp LP, TX, USA). Descriptive statistics were presented for the overall sample 
and by ACB score groups and compared using one-way analysis of variance for means, 
and Pearson’s Chi-squared test for categorical measures. 
 
Cox-proportional hazards models were constructed to determine the associations between 
ACB and the risk of incident stroke and incident stroke mortality using ACB score 0 group 
as the reference category. Adjusted analyses were undertaken to account for potential 
confounding factors such as age, sex, lifestyle, socioeconomic, co-morbidities, stroke risk 
factors such as blood pressure and cholesterol levels, use of primary prevention 
medications such as aspirin. A variety of adjusted models were used to assess the effects 
of these potential confounding factors in a group sequential fashion. Model A adjusted for 
age and sex; model B adjusted for age, sex, smoking, alcohol consumption, physical 
activity level, education level, occupational social class, systolic blood pressure, cholesterol 
level and body mass index; model C adjusted for variables in model B plus prevalent 
asthma, COPD, diabetes, MI and cancer; model D adjusted for variables in model B as well 
as excluding people with prevalent asthma, COPD, diabetes, MI and cancer; model E 
adjusted for variables in model C as well as excluding all events occurring within first two 
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years of follow up; model F adjusted for variables in model C plus aspirin use; model G 
adjusted for variables in model B truncated at 5 years follow-up; model H adjusted for 
variables in model B truncated at 10 years follow-up; model I was propensity adjusted, 
based on propensity score estimated from factors in model B. Cox-proportional Hazards 
Ratios (HR) for incident stroke subdivided into those with ischaemic strokes (ICD category 
I63) and those with haemorrhagic strokes (ICD category I61) adjusted for variables in 
model C was also performed. 
 
 
As ACB was calculated from the baseline we examined the relationship using shorter follow 
up periods (models G and H) to determine if the outcomes varied depending on follow up 
duration and repeated the analyses after exclusion of individuals with strokes occurring 
within the first two years of follow up to account for reverse causality (model E) as well as 
after excluding other prevalent illness (model D).  
 
An alternative analysis was performed using propensity score analysis (model I). Individuals 
were matched using estimated propensity scores from a logistic regression model based on 
covariates that predict ACB group.  This was done 3 times, once for each comparison for 
ACB score of 0. The matched pairs were then entered into an unadjusted Cox-regression 
model.  
 
Kaplan-Meier curves were constructed for the 4 different ACB score groups. The end-point 
was incident stroke, which included both fatal and non-fatal strokes. All statistical tests were 
assessed at two-sided significance level of 0.05. 
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Results 
 
In total 25,639 participants attended the first health check, 3,917 participants were excluded 
due to prevalent stroke at the baseline (n= 388) and those with any missing data on the 
variables included in the analysis, leaving 21,722 study participants eligible to be included 
in the analysis. Most variables with missing data has less then <1% missing, with the 
highest missing data exclusion for missing cholesterol levels. The mean age of participants 
(SD) was 58.9 (9.2) years and 54.4% were women. Of these, 2,131 suffered an incident 
stroke and 562 participants died from stroke. The mean follow up (SD) for incident stroke 
was 17.77(4.91) years (total person years 385,979) and 18.05 (4.73) years (total person 
years 392,176) for stroke mortality.  
 
Table 1 details sample characteristics at baseline and crude outcome rates during the 
whole follow up period by total ACB score groups. Differences were observed across all 
ACB groups for all variables aside from sex.  The participants in the higher ACB score 
groups at study baseline had a greater age, were physically less active, had higher total 
cholesterol levels, higher systolic blood pressure and were more likely to be on primary 
prevention medications for stroke such as aspirin, lipid lowering drugs and antihypertensive 
drugs. They were more likely to have had a diagnosis of COPD, asthma and diabetes. 
Higher ACB is also associated with higher proportion of participants in lower occupational 
social classes and those with lower educational attainment. 
 
Higher crude rates of events for both incident stroke and stroke mortality occurred in higher 
ACB score groups. Over the entire follow up the overall crude stroke event rates were  
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8.5%, 14.4%, 15.8% and 16.0% and the crude stroke mortality rates were  2.1%, 4.6%, 
3.4% and 5.3% for ACB score 0, 1, 2-3 and >3 groups, respectively. 
 
Table 2 details the Cox-proportional Hazards Ratios (HR) and corresponding 95% 
confidence intervals (95% CI) for incident stroke and stroke mortality across the 4 ACB 
score groups using ACB score of 0 group as the reference category.  Higher ACB score 
groups were associated with a higher risk of incident stroke and stroke death. The models 
of adjustment with incremental inclusion of various confounders were associated with 
attenuation in HRs but the risk remained high. The participants in highest ACB group (ACB 
>3) had increase in relative risk of 59% and 86% for incident stroke and incident stroke 
mortality, respectively, compared to those with ACB of 0 in the fully adjusted model (model 
C). Excluding participants with prevalent medical conditions, events occurring within the first 
two years of follow up, truncation of follow-up at shorter time frames of 5 and 10 years and 
propensity score analysis only slightly attenuated the results.   
 
Table 3 details the Cox-proportional Hazards Ratios (HR) and corresponding 95% 
confidence intervals (95% CI) for incident stroke subdivided into those with ischaemic 
strokes (ICD category I63) and those with haemorrhagic strokes (ICD category I61) 
adjusted for variables in model C. Higher ACB groups were associated with higher risk of 
incident ischaemic stroke but not for haemorrhagic stroke. Stroke mortality was not 
calculated due to small samples sizes (see Table 1 for participant numbers). 
 
Figure 1 shows Kaplan-Meier curves for time to incident stroke for ACB score groups 0, 1, 
1-2 and >3. The end-point was incident stroke, which included both fatal and non-fatal 
strokes. Higher ACB groups had a shorter time to incident stroke (p<0.001). 
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Table 1 here. 
Table 2 here. 
Table 3 here 
Figure 1 here. 
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Discussion 
To the best of our knowledge, this is the first study to examine the association between 
ACB from medications and the subsequent risk of stroke in an apparently healthy general 
population. Our results show that participants with higher baseline ACB scores were at an 
increased risk of stroke incidence and stroke related mortality compared to the ACB 0 
reference group. Participants with higher anticholinergic burden were older, more likely to 
have prior co-morbidities and cerebrovascular risk factors, but adjustment for these 
variables and other potential confounders yielded similar results.  
 
In the fully adjusted model (model C) those with an ACB of greater than 3 had a HR (95% 
CI) of 1.59 (1.34 - 1.89) for incident stroke and 1.86 (1.37 - 2.53) for stroke mortality. 
Importantly, a reduction from one ACB category to another also represents an important 
reduction in risk. Given the wide variety of medications that exhibit anticholinergic 
properties a vitally important message to prescribers is that even small changes in a 
patient’s drug regimen can result in a considerable risk reduction.  
 
Little research has been published examining a link between ACB and stroke risk in general 
population with most studies focusing on inhaled anticholinergic medication in COPD 
patients, with mixed results. One population-based nested case–control study in 15,396 
newly-diagnosed COPD patients showed an increased risk (Adjusted Odds Ratio, 2.02; 
95% CI, 1.71 - 2.41) of stroke in those treated with ipratropium within 6 months (17), 
whereas another study showed no increase in risk of all-cause stroke from inhaled 
anticholinergics in a UK primary care derived population (18). A meta-analysis of 17 
randomised placebo or active controlled trials showed that there was no increased in the 
risk of stroke (RR, 1.46 [95% CI, 0.81-2.62]; P=.20, I2=0%) in patients with COPD taking 
 15 
inhaled tiotropium or ipratropium (11).  These findings were echoed by another meta-
analysis of 19 randomised control (placebo or salmeterol) trials showed that tiotropium did 
not increase the risk of non-fatal stroke (RR = 1.04; 95% CI, 0.78-1.39, I2 0%) (12).  
 
It can be observed that the 95% CIs overlap for ACB score groups 1, 2-3 and > 3 for 
models B-D. This may suggest that the major jump in risk is between those with no ACB 
and those with ACB of at least 1. However, this maybe a reflection of the sample size and 
we would expect that these 95% CIs to be narrower in a larger population. 
 
Mechanistically, potential explanations exist for why there is a plausible causal link between 
ACB from medications and increased incidence of stroke and stroke related death.  It has 
been suggested that anticholinergic medications have pro-arrhythmic and pro-ischaemic 
properties, which may lead to cerebral ischaemia (19). Anticholinergic drugs act to 
suppress parasympathetic stimulation to the heart, which is associated with 
tachyarrhythmias. These arrhythmias confer an increased risk of embolic strokes as well as 
cardiac ischaemia and sudden death in susceptible cardiac patients (20). It has been 
shown previously that the arterial baroreflex is a vital mechanism that plays an important 
role in determining many stroke outcomes, including prognosis (21). It has been suggested 
that vagal nerve activity may be involved in the protective effects of the baroreflex in stroke 
and that loss of parasympathetic activation in increasing age and cardiovascular disease 
attenuates this protective effect (22). It stands to reason that interference of vagal tone by 
antimuscarinic medication could have a similar effect.  
 
Effects through immunomodulation by the cholinergic system may also serve as a potential 
mechanism. Both experimental and clinical evidence has demonstrated inflammation as an 
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important component of stroke aetiology and pathophysiology (23). The cholinergic system 
regulates immune response as nicotinic receptor activation leads to inhibition of the innate 
and adaptive immune systems and muscarinic receptor antagonists have been shown to 
inhibit T-cell proliferation, response and migration. Interference of these systems may lead 
to an inappropriate inflammatory response (24, 25). 
 
As shown in table 3, an increase in risk of incident stroke was demonstrated in higher ACB 
categories for those with ischaemic stroke but not for those with haemorrhagic stroke. This 
may be due to the fact that the above mechanisms are more likely to be relevant to the 
pathophysiology of the ischaemic stroke. However, the numbers of haemorrhagic strokes 
were relatively small in our data set and it is likely this was under powered to detect a 
meaningful difference. Future population studies should be conducted to examine this in a 
larger population. 
 
Our study has several strengths. We used a large population based sample, which 
improves the generalisability of our findings. As a prospective study, with robust case 
ascertainment, we introduce less bias. We used a well validated ACB score. Further, we 
were able to control for a wide range of demographic, lifestyle and socioeconomic factors, 
as well as for medical co-morbidities and concomitant primary preventive medications for 
stroke, and additionally performed propensity score matched analysis. There is no reason 
to believe potential mechanistic link between ACB and stroke risk would differ in different 
races and thus our study has global implication with regard to reducing global stroke 
burden. 
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There are some limitations worth discussing. It could be argued that we introduced healthy 
volunteer bias as this was a volunteer study which required long-term follow up. 
Nevertheless, the baseline characteristics of the EPIC-Norfolk have been shown to be 
similar to other UK representative population samples (14). Approximately 3,500 
participants were excluded due to missing data, however the examination of percentage 
missing demonstrated most missing variables were <1% missing. This is unlikely to have 
significantly attenuated the observed associations. EPIC-Norfolk participants are mainly 
Caucasians (>99.6%) but as eluded earlier in the strengths of this study, the biological 
mechanism between the link between anticholinergic and risk of outcomes examined is 
unlikely to be different between different races.  
 
Reverse causality is a major factor in measuring the association between medications and 
health outcomes. To further understand this effect, we excluded events that occurred within 
the first two years and the observed associations remained after this adjustment. As ACB 
was calculated at baseline, we do not know whether participants continued this medication 
regimen throughout the follow up period. To account for this, we truncated our analysis 
using shorter follow up periods of 5 and 10 years, shown in Table 2 as models G and H. 
The results were broadly similar for these different follow up periods. Furthermore, it is likely 
ACB burden increases with increasing age and this applies to all ACB groups. 
 
Potential confounders were measured at baseline and it is possible that these may vary 
during the follow up period. However, truncation of the analysis at 5, 10 and 15 years only 
slightly attenuated the results. Whilst both multivariable adjustment and propensity score 
analyses were performed to assess the impact of known available confounders we 
recognise that residual and unmeasured confounding could not be ruled out. 
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Those in higher ACB groups had a higher cardiovascular risk profile and hence were 
potentially more likely to be followed up thus introducing possible surveillance bias. 
However, endpoint ascertainment was based on validated record linkage system within UK 
NHS, which limits any potential surveillance bias. 
 
Implications 
International guidance on the management of polypharmacy recommends ‘medicines 
optimisation’, in partnership with patients, to attain the best possible outcomes and avoid 
inappropriate polypharmacy (26, 27). A multidisciplinary approach is required to tackle this 
issue with pharmacists and primary care providers being in an ideal position to monitor and 
adjust medicine usage. It is important to note, polypharmacy can be appropriate and 
anticholinergic medicines often play a central role in disease management. Of note, 
polypharmacy does not necessarily equate to high anticholinergic burden and it is possible 
to reduce anticholinergic burden through processes such as switching to medications with 
similar pharmacological effects but without anticholinergic properties. Where polypharmacy 
does occur, we encourage clinicians to carefully consider prescribing medications with ACB 
and offer alternatives when feasible. As stroke is one of the leading causes of mortality and 
morbidity, reduction of ACB at the population level has huge potential impact on reducing 
the growing global burden of stroke. 
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Conclusion 
Our study has shown a dose-response relationship between ACB from medications and risk 
of incident stroke and stroke mortality in a large, general population. In absence of long 
term population based clinical trials which examine the impact of reducing ACB at the 
general population level, our results provide incentive to patients, public, and clinicians to 
use medications with anticholinergic properties cautiously to reduce risk of stroke and 
subsequent global burden of stroke.   
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Table 1 Baseline sample characteristics of 21,722 men and women of the EPIC-Norfolk and crude outcome rates during the whole follow up according to the 
total anticholinergic burden score groups 
 
 All 
 
(n= 21,722) 
ACB score 0 
group 
(n= 17,467) 
ACB score 1 
group 
(n= 2,179) 
ACB score 2-3 
group (n=1,157) 
ACB score >3 
group (n=919) 
P* 
Mean age years (SD) 58.9 (9.2) 58.0 (9.1) 62.23 (8.8) 63.30 (9.02) 63.35 (8.6) <0.001 
Sex (%) 
Men 
Women 
 
9913 (45.6) 
11809 (54.4) 
 
7946 (45.5) 
9521 (54.5) 
 
1016 (46.6) 
1163 (53.4) 
 
531 (45.9) 
626 (54.1) 
 
420 (45.7) 
499 (54.3) 
0.79 
Social class (%) 
Professional 
Manager 
Skilled non-manual 
Skilled manual 
Semi-skilled 
Unskilled 
 
1546 (7.1) 
8048 (37.0) 
3621 (16.7) 
 
4973 (22.9) 
2817 (13.0) 
707 (3.3) 
 
1291 (7.4) 
6595 (37.8) 
2859 (16.4) 
 
3962 (22.7) 
2224 (12.7) 
535 (3.1) 
 
138 (6.3) 
767 (35.2) 
385 (17.7) 
 
496 (22.8) 
309 (14.2) 
84 (3.9) 
 
64 (5.5) 
408 (35.3) 
198 (17.1) 
 
276 (23.9) 
161 (13.9) 
50 (4.3) 
 
53 (5.8) 
278 (30.3) 
179 (19.5) 
 
238 (25.9) 
133 (14.5) 
38 (4.1) 
<0.001 
Smoking (%) 
Current-smoker 
Ex-smoker 
Never smoker 
 
2421 (11.1) 
9227 (42.5) 
10074 (46.4) 
 
1988 (11.4) 
7195 (41.2) 
8284 (47.4) 
 
199 (9.1) 
1044 (47.9) 
936 (43.0) 
 
120 (10.4) 
559 (48.3) 
478 (41.3) 
 
114 (12.4) 
429 (46.7) 
376 (40.9) 
<0.001 
Alcohol use (units/week) 
(SD) 
7.15 (9.35) 7.34 (9.44) 6.73 (9.53) 6.18 (8.30) 5.77 (8.20) <0.001 
Education level (%) 
No qualification 
0-Level 
A-Level 
Higher degree 
 
7698 (35.4) 
2269 (10.4) 
8915 (41.0) 
2840 (31.1) 
 
5859 (33.5) 
1882 (10.8) 
7282 (41.7) 
2444 (14.0) 
 
905 (41.5) 
210 (9.6) 
845 (38.8) 
219 (10.1) 
 
505 (43.6) 
97 (8.4) 
455 (39.3) 
100 (8.6) 
 
429 (46.7) 
80 (8.7) 
333 (36.2) 
77 (8.4) 
<0.001 
Physical activity (%) 
Inactive 
Moderately inactive 
Moderately active 
Active 
 
6319 (29.1) 
6294 (29.0) 
5044 (23.2) 
4065 (18.7) 
 
4636 (26.5) 
5096 (29.2) 
4252 (24.3) 
3483 (19.9) 
 
816 (37.4) 
618 (28.4) 
434 (19.9) 
311 (14.3) 
 
468 (40.4) 
320 (27.7) 
205 (17.7) 
164 (14.2) 
 
399 (43.4) 
260 (28.3) 
153 (16.6) 
107 (11.6) 
<0.001 
Cholesterol (mmol/L) 
(SD) 
6.17 (1.16) 6.13 (1.15) 6.31 (1.21) 6.30 (1.21) 6.42 (1.24) <0.001 
Systolic BP (mmHg) (SD) 135.05 (18.2) 134.11 (17.90) 139.24 (18.47) 136.76 (18.81) 140.78 (19.43) <0.001 
BMI (kg/m2)** (SD) 26.26 (3.8) 26.10 (3.72) 26.88 (4.20) 26.78 (4.03) 27.19 (4.16) <0.001 
COPD (%) 2008 (9.2) 1437 (8.2) 301 (13.8) 160 (13.8) 110 (12) <0.001 
Asthma (%) 1809 (8.3) 923 (5.3) 587 (26.9) 173 (15.0) 126 (13.7) <0.001 
Diabetes*** (%) 460 (2.1) 286 (1.6) 70 (3.2) 52 (4.5) 52 (5.7) <0.001 
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MI (%) 656 (3.0) 250 (1.4) 156 (7.2) 149 (12.9) 101 (11.0) <0.001 
Cancer (%) 1168 (5.4) 886 (5.1) 131 (6.0) 91 (7.8) 60 (6.5) <0.001 
Aspirin use # (%) 1920 (10.4) 1168 (7.7) 325 (18.3) 236 (24.2) 191 (25.8) <0.001 
Antihypertensive use (%) 3882 (17.9) 1595 (9.1) 1106 (50.8) 557 (48.1) 295 (32.1) <0.001 
Lipid lowering 
medication use (%) 
314 (1.4) 166 (1) 61 (2.8) 43 (3.7) 44 (4.8) <0.001 
New incident stroke (%) 2131 (9.8) 1487 (8.5) 314 (14.4) 183 (15.8) 147 (16.0)  
      Haemorrhage 374 (1.7) 281 (1.6) 49 (2.3) 22 (1.9) 22 (2.4)  
      Infarct 956 (4.4) 667 (3.8) 132 (6.1) 90 (7.8) 67 (7.3)  
Stroke Deaths (%) 562 (2.6) 374 (2.1) 100 (4.6) 39 (3.4) 49 (5.3)  
      Haemorrhage 156 (0.7) 108 (0.6) 26 (1.2) 14 (1.2) 8 (0.9)  
      Infarct 79 (0.4) 54 (0.3) 12 (0.6) 3 (0.3) 10 (1.1)  
 
Values presented are mean (SD) for continuous and number (%) for categorical data. *overall P value. BP=blood pressure, BMI = body mass index, COPD= 
chronic obstructive pulmonary disease and MI=myocardial infarction. Total anticholinergic burden (ACB) calculated as a score which is the sum of the 
[number of class 1 anticholinergic drugs, the number of class 2 anticholinergic drugs x2 and the number class 3 anticholinergic drugs x3].  Classification of 
drugs with ACB class 1, 2 and 3 based on criteria of Anticholinergic Cognitive Burden Scale15. ** n = 21,707, *** n = 21,713, # 1,920 events total 18,532. 
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Table 2: Hazard ratios and their corresponding 95%CI of incident stroke and stroke mortality according to total anticholinergic burden score groups during 
follow up in EPIC-Norfolk 
 
 
Models  
Incident Stroke 
(Events (n=2,131)/Total N=21,722) 
ACB score 0 group ACB score 1 group ACB score 2-3 group ACB score >3 group 
A 1.00 1.39 (1.23 – 1.58) 1.58 (1.35 – 1.84) 1.72 (1.45 – 2.04) 
B 1.00 1.36 (1.20 – 1.53) 1.60 (1.37 – 1.87) 1.68 (1.42 – 1.99) 
C 1.00 1.33 (1.17 – 1.51) 1.54 (1.31 – 1.80) 1.59 (1.34 – 1.89) 
D 
 
1.00 1.32 (1.13 – 1.55) 1.61 (1.32 – 1.95) 1.88 (1.53 – 2.30) 
E 
 
1.00 1.32 (1.16 – 1.50) 1.55 (1.32 – 1.81) 1.57 (1.32 – 1.87) 
F 1.00 1.28 (1.11 – 1.48) 1.34 (1.11 – 1.61) 1.53 (1.26 – 1.86) 
G 1.00 1.27 (0.81 – 1.98) 1.27 (0.71 – 2.27) 2.08 (1.26 – 3.45) 
H 1.00 1.58 (1.25 – 2.00) 1.84 (1.38 – 2.45) 2.46 (1.86 – 3.25) 
I 1 1.35 (1.19 – 1.52) 1.56 (1.38 – 1.83) 1.64 (1.38 – 1.94) 
 
Models  
Stroke Mortality (114) 160 – 169 
(Events (n=562)/Total N=21,722) 
ACB score 0 group ACB score 1 group ACB score 2-3 group ACB score >3 group 
A 1.00 1.57 (1.25 – 1.96) 1.13 (0.81 – 1.58) 1.95 (1.44 – 2.63) 
B 1.00 1.55 (1.24 – 1.94) 1.19 (0.85 – 1.66) 1.94 (1.44 – 2.62) 
C 1.00 1.58 (1.25 – 1.99) 1.16 (0.83 – 1.62) 1.86 (1.37 – 2.53) 
D 
 
1.00 1.56 (1.17 – 2.07) 1.03 (0.66 – 1.62) 2.24 (1.58 – 3.18) 
E 
 
1.00 1.57 (1.24 – 1.98) 1.19 (0.85 – 1.67) 1.87 (1.37 – 2.54) 
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F 1.00 1.56 (1.21 – 2.02) 0.97 (0.65 – 1.45) 1.84 (1.31 – 2.59) 
G 1.00 1.37 (0.59 – 3.15) 1.10 (0.33 – 3.64) 2.56 (1.05 – 6.25) 
H 1.00 1.76 (1.15 – 2.71) 1.38 (0.75 – 2.54) 3.11 (1.92 – 5.04) 
I 1.00 1.54 (1.23 – 1.93) 1.14 (0.81 – 1.59) 1.90 (1.40 – 2.57) 
 
ACB = Anticholinergic burden score.  
Model A: n/N=2,131/21,722 for incident stroke, n/N= 562/21,722 for stroke mortality analysis; adjusted for age and sex. 
Model B: n/N=2,129/21,707 for incident stroke, n/N= 562/21,707 for stroke mortality analysis; Model A plus smoking, alcohol consumption, physical activity 
level, education level, occupational social class, systolic blood pressure, cholesterol level and body mass index. 
Model C: n/N=2,123/21,685 for incident stroke, n/N= 561/21,685 for stroke mortality events analysis; Model B plus prevalent conditions asthma, COPD, 
diabetes, MI and cancer.  
Model D:  n/N=1,544/16,547 for incident stroke, n/N= 400/16,547 for stroke mortality analysis; as in Model B excluding people with prevalent asthma, COPD, 
diabetes, MI and cancer.  
Model E: n/N=2,095/21,448 for incident stroke, n/N= 549/21,448 for stroke mortality events analysis; as in Model C excluding all events occurring within first 
two years of follow up. 
Model F: n/N=1,704/18,500 for incident stroke, n/N= 454/18,500 for stroke mortality events; Model C plus aspirin use.  
Model G: n/N=161/ 21,707   for incident stroke, n/N= 44 / 21,707 for stroke mortality events analysis; Model B truncated at 5 years follow-up 
Model H: n/N= 524/ 21,707 for incident stroke, n/N= 148/ 21,707 for stroke mortality events analysis; Model B truncated at 10 years follow-up 
Model I: Propensity adjusted: Based on propensity score estimated from factors in Model B. 
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Table 3: Hazard ratios and their corresponding 95%CI of incident stroke according to total anticholinergic burden score groups during follow up in EPIC-
Norfolk subdivided into ischaemic and haemorrhagic stroke sub types adjusted for age, sex, smoking, alcohol consumption, physical activity level, education 
level, occupational social class, systolic blood pressure, cholesterol level, body mass index, asthma, COPD, diabetes, MI and cancer (model C). 
 
 
Stroke 
subtype 
Incident Stroke 
(Total N=21,722) 
ACB score 0 group ACB score 1 group ACB score 2-3 group ACB score >3 group 
Ischaemic 
(total events = 
956) 
1.00 1.29 (1.07 – 1.57) 1.73 (1.38 – 2.17) 1.60 (1.23 – 2.07) 
Haemorrhagic 
(total events = 
374) 
1.00 1.13 (0.82 – 1.56) 1.03 (0.66 – 1.60) 1.38 (0.88 – 2.14) 
 
 26 
Figure 1: Kaplan-Meier curves for time to incident stroke for ACB score categories during follow up in EPIC-Norfolk 
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X-axis - Analysis time in years 
Y-axis – Cumulative probability of not having incident stroke, which includes both fatal and non-fatal strokes. 
Number at risk – number of participants at risk of incident stroke per time interval 
ACB = Anticholinergic burden score
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Appendix 1: Anticholinergic Cognitive Burden scoring of drugs 
 
Score 1 Score 2 Score 3 
Alimemazine Amantadine Amitriptyline 
Alverine Belladone alkaloids Amoxapine 
Alprazolam  Atropine 
Atenolol Cyclobenzaprine Benztropine 
Brompheniramine maleate Cyproheptadine Brompheniramine 
Bupropion hydrochloride Empracet Carbinoxamine 
Captopril Loxapine Chlorpheniramine 
Chlorthalidone Meperidine Chlorpromazine 
Cimetidine hydrochloride Methotrimeprazine Clemastine 
Ranitidine Molindone Clomipramine 
Clorazepate Oxcarbazepine Clozapine 
Codeine 
Pethidine 
hydrochloride 
Darifenacin 
Colchicine Pimozide Desipramine 
Coumadin  Dicyclomine 
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Score 1 Score 2 Score 3 
Diazepam  Dimenhydrinate 
Digoxin  Diphenhydramine 
Dipyridamole  Doxepin 
Disopyramide phosphate  Flavoxate 
Fentanyl  Hydroxyzine 
Furosemide  Hyoscyamine 
Fluvoxamine  Imipramine 
Haloperidol  Meclizine 
Hydralazine  Nortriptyline 
Hydrocortisone  Olanzapine 
Isosorbide  Orphenadrine 
Loperamide  Oxybutynin 
Metoprolol  Paroxetine 
Morphine  Perphenazine 
Nifedipine  Procyclidine 
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Score 1 Score 2 Score 3 
Prednisone  Promazine 
Quinidine  Promethazine 
Risperidone  Propentheline 
Theophylline  Pyrilamine 
Trazodone  Quetiapine 
Triamterene  Scopolamine 
  Thioridazine 
  Tolterodine 
  Trifluoperazine 
  Trihexyphenidy 
  Trimipramine 
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Appendix 2 Table showing numbers and proportions of participants with missing data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Missing data Proportion (%) 
Data unable to be released 3 0.012 
Prevalent stroke 388 1.51 
Social class 541 2.11 
Smoking  183 0.71 
Alcohol use 217 0.85 
Physical activity  1 0.0039 
Cholesterol level 1,628 6.35 
Systolic blood pressure 38 0.15 
Missing data on co-
morbidities 
23 0.09 
Total fruit intake 886 3.46 
Total veg intake 9 0.035 
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Appendix 3 Flow diagram of participants included in the study with reasons and numbers 
of those excluded 
 
21,722 participants included 
in the analysis. 
25639 participants attended 
first health check. 
3917 participants excluded (n) 
 Data unable to be released (3) 
 Prevalent stroke (388) 
 Social class (541) 
 Smoking (183) 
 Alcohol use (217) 
 Physical activity (1) 
 Cholesterol level (1,628) 
 Systolic blood pressure (38) 
 Missing data on co-morbidities (23) 
 Total fruit intake (886) 
 Total veg intake (9) 
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Measurement methods 
 
Trained nurses examined individuals at clinic visit. Weight was measured with participants wearing light clothing 
without shoes.  Height was measured up to the nearest 0∙1 cm using a stadiometer with shoes removed.  Body mass index 
(BMI) was calculated as weight (kilogram) divided by height in metres squared (m2). Blood pressure (BP) was measured 
with an Accutorr monitor (Datascope, Huntingdon, UK) after the participant had been seated for 5 min. We used the 
mean of two BP measurements for analysis. Non-fasting venous blood samples were taken into plain and citrate bottles. 
We measured serum total cholesterol with the RA 1000 (Bayer Diagnostics, Basingstoke, UK). 
At the baseline participants completed a detailed health and lifestyle questionnaire. Participant’s educational status, 
occupational social class, and physical activity were obtained from the baseline health and lifestyle questionnaire. 
Educational status was recorded as no qualification, O- level, A-level, degree or higher qualification. Social class was 
classified according to the Registrar General’s occupation-based classification scheme. A four-level physical activity 
index was derived from the validated EPIC short physical activity questionnaire designed to assess combined work and 
leisure activity.  For stratified analyses, social class was re-categorised into manual (III-manual, IV and V) and non-
manual (III-non-manual, II and I), educational attainment was re-categorised as low educational attainment (no or O 
level) and high educational attainment (at least A level) and physical activity was re-categorised as high (active and 
moderately active) and low (inactive and moderately inactive) physical activity categories.  
 
Smoking status was categorised as current smoker, ex-smoker and those who have never-smoked.  “Current smokers” 
were defined as those who answered “yes” to the question “Do you smoke cigarettes now?”.  “Never smokers” were 
defined as those who answered “no” to the question “Have you ever smoked as much as one cigarette a day for as long 
as a year?”  All others were classed as “former smokers”. Average alcohol consumption (units/week) was derived from 
a food frequency questionnaire (FFQ) completed at the baseline.  Prevalent illnesses were determined by a positive 
response to the question “Has a doctor ever told you that you have any of the following?” followed by a list of options 
including asthma, COPD, cancer, stroke, heart attack, and diabetes.   
 
Aspirin, steroid tablets or injections and diuretics use was ascertained by a question “Have you taken (aspirin, steroid 
tablets or injections and diuretics) continuously for three months or more?”.  Other medications were identified by 
participant’s response to the question “In the last week have you taken any drugs or medicines either prescribed by your 
doctors or bought from the chemist? If YES, please name them.”  The medication name or brand, dose and frequency of 
administration were recorded and each medication was coded exactly as written in the baseline survey into a database.   
 
Patient and public engagement in research project 
We have engaged with general practitioners and participants throughout the study design, from first inception to final 
conduct of the study. We conduct regular advisory meetings 3-4 times a year with our advisory panel of participants. We 
seek advice from the panel on study design and conduct.  Components such as questionnaire development and outcome 
measures were informed by participants’ priorities, preferences and experiences. It is our policy to acknowledge the 
participants in every publication and dissemination of materials (posters and PowerPoint presentations). We regularly 
disseminate the research findings to participants through newsletters, participants’ meetings and public engagement 
events. EPIC-Norfolk celebrated its 20th anniversary recently and participants received personalised information. 
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